Feb 27 |
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
|
Feb 27 |
Can Aclaris Therapeutics (NASDAQ:ACRS) Afford To Invest In Growth?
|
Feb 20 |
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
|
Feb 15 |
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
|
Jan 22 |
HW Wainwright cuts Aclaris to neutral, cites underwhelming study data
|
Jan 22 |
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
|
Jan 17 |
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
|
Jan 16 |
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
|
Jan 16 |
Aclaris spikes after leadership change, strategic review
|
Jan 16 |
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
|